CHANGES IN SERUM LEVELS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND THEIR RELATIONSHIP WITH THE PROGRESSION OF CHRONIC KIDNEY DISEASE
Journal of IMAB - Annual Proceeding (Scientific Papers) · 06.08.2026 · 32 (3) · 6996-7001
DOI: 10.5272/jimab.2026323.6996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of IMAB - Annual Proceeding (Scientific Papers), online erschienen am 06.08.2026. Verfasst von Borislav Ignatov und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic kidney disease (CKD) affects over 10% of the global population, posing significant challenges due to its asymptomatic nature in early stages and progressive deterioration of renal function. The identification of reliable biomarkers for early diagnosis and monitoring of disease progression is crucial for improving prognosis and treatment. Neutrophil gelatinase-associated lipocalin (NGAL) is a promising candidate, already validated as a marker for acute kidney injury.
Purpose
This study aimed to evaluate the potential of serum NGAL levels as a biomarker for diagnosis and monitoring the progression of CKD. Material/Methods: Seventy-one adult Caucasian patients at CKD stages G1–G4 according to the KDIGO criteria were divided into three groups: Group 1 (eGFR ≥90 mL/min/1.73m²), Group 2 (eGFR 45–89 mL/min/1.73m²), and Group 3 (eGFR 15–44 mL/min/1.73m²). Blood samples were collected and analyzed via standard biochemical and immunological techniques. Serum NGAL levels were measured using ELISA.
Results
NGAL levels increased significantly with disease progression and strongly correlated with declining eGFR. Higher NGAL levels were linked to elevated serum creatinine and inflammatory markers, indicating progressive damage to the kidney tissue against the backdrop of persistent systemic inflammation.
Conclusions
As a biomarker, NGAL has significant potential for identifying and monitoring kidney damage. Its application in clinical settings could complement and improve existing methods for diagnosing and observing CKD.
Zitieren
APA
Ignatov, B., Kostov, K., Eftimova, T., Blazhev, A., & Simeonova, T. (2026). CHANGES IN SERUM LEVELS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND THEIR RELATIONSHIP WITH THE PROGRESSION OF CHRONIC KIDNEY DISEASE. Journal of IMAB - Annual Proceeding (Scientific Papers), 32(3), 6996-7001. https://doi.org/10.5272/jimab.2026323.6996
Vancouver
Ignatov B, Kostov K, Eftimova T, Blazhev A, Simeonova T. CHANGES IN SERUM LEVELS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND THEIR RELATIONSHIP WITH THE PROGRESSION OF CHRONIC KIDNEY DISEASE. Journal of IMAB - Annual Proceeding (Scientific Papers). 2026;32(3):6996-7001. doi:10.5272/jimab.2026323.6996
BibTeX
@article{Ignatov2026,
author = {Ignatov, Borislav and Kostov, Krasimir and Eftimova, Tsvetelina and Blazhev, Alexander and Simeonova, Tatyana},
title = {CHANGES IN SERUM LEVELS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND THEIR RELATIONSHIP WITH THE PROGRESSION OF CHRONIC KIDNEY DISEASE},
journal = {Journal of IMAB - Annual Proceeding (Scientific Papers)},
year = {2026},
volume = {32},
number = {3},
pages = {6996--7001},
doi = {10.5272/jimab.2026323.6996}
}
EUVIMED